Chroma Medicine, a Boston-based biotech startup, has conducted layoffs as part of a strategic shift.

The company is preparing to move its first epigenetic editors into human testing.

Chroma's drugs are designed to alter gene expression via methylation, without altering the DNA itself.

Since launching in 2021, Chroma has secured over $250 million in funding, with a significant $135 million from a Series B round last year.

The layoffs are seen as a realignment of resources to focus on the company's progression into clinical development.